Merus Labs International Inc (TSE:MSL) (NASDAQ:MSLI) had its price objective reduced by TD Securities from C$3.00 to C$1.65 in a report published on Friday, May 12th. They currently have a tender rating on the specialty pharmaceutical company’s stock.
MSL has been the topic of a number of other reports. Scotiabank reaffirmed a sector perform rating and set a C$1.25 price objective on shares of Merus Labs International in a research note on Monday, February 13th. CIBC dropped their target price on shares of Merus Labs International from C$1.50 to C$1.40 in a report on Wednesday, February 15th. Finally, Bloom Burton restated a hold rating on shares of Merus Labs International in a report on Monday, February 13th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of C$1.99.
Shares of Merus Labs International (TSE MSL) traded up 0.62% during midday trading on Friday, hitting $1.63. The stock had a trading volume of 82,920 shares. The firm’s 50-day moving average is $1.47 and its 200 day moving average is $1.23. Merus Labs International has a one year low of $0.95 and a one year high of $1.76. The company’s market capitalization is $191.29 million.
TRADEMARK VIOLATION NOTICE: “Merus Labs International Inc (MSL) Price Target Cut to C$1.65” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.com-unik.info/2017/06/17/merus-labs-international-inc-msl-pt-lowered-to-c1-65-at-td-securities-updated-updated-updated.html.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
What are top analysts saying about Merus Labs International Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Merus Labs International Inc and related companies.